Dmitry Gabrilovich
Program Director/Principal Investigator :
BIOGRAPHICAL SKETCH
Provide the following information for the key personnel in the order listed for Form Page 2.
Follow the sample format on preceding page for each person. DO NOT EXCEED FOUR PAGES.
NAME
POSITION TITLE
Dmitry Gabrilovich, MD, PhD
Professor of Interdisciplinary Oncology
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include
postdoctoral training.)
INSTITUTION AND LOCATION
Kabardino-Balkarian State University, Medical School,
Nalchik, Russia
Central Institute for Epidemiology, Moscow, Russia
Central Institute for Epidemiology, Moscow, Russia
DEGREE
(if applicable)
YEAR(s)
FIELD OF STUDY
MD
1984
Medicine
PhD
1986
1989
Infectious diseases
Immunology
A.Positions and Honors.
Positions and Employment
08/2005 – present Professor of Interdisciplinary Oncology, University of South Florida, Tampa, FL
08/2005 – present Professor of Microbiology and Immunology, Molecular Biology and Biochemistry, University
of South Florida, Tampa, FL
09/00-08/05 Associate Professor of Oncology, H. Lee Moffitt Cancer Center, University of South Florida,
Tampa, FL
01/99-09/00 Assistant Professor of Pathology, Loyola University Medical Center, Maywood, IL
06/97-12/98 Research Assistant Professor, Vanderbilt University, Nashville, TN
06/96-06/97 Research Instructor, Vanderbilt University, Nashville,TN
10/94-06/96 Research Fellow, UT Southwestern Medical Center, Dallas, TX
09/92-09/94 Research Fellow, St. Mary’s Hospital Medical School, London, UK
Other Experience and Professional Memberships
1999-2006 scientific reviewer on DoD study sections for Prostate Cancer and Breast Cancer Programs and
CTV-1 study section for Breast Cancer Program
2001 – 2005 member EI/TTT study section (NIH)
2006 – ad hoc member of TME study section, PO1 review committees (NIH), and CMI-B study section
2001 – reviewer on MOG study section American Cancer Society
B. Selected peer-reviewed publications (in chronological order)
Selected Most Recent Peer-Reviewed Publication from Total of 97 Publications
Antonia SJ., Mirza N, Fricke I., Chiappori A., Thompson P., Williams N., Bepler G., Simon G., Janssen W., Lee
J-H., Menander K., Chada S., Gabrilovich DI. Combination of p53 cancer vaccine with chemotherapy in
patients with extensive stage small cell lung cancer. Clin. Cancer Res. 2006, 12: 878-887.
Nefedova Y., Nagaraj S., Rosenbauer A., Muro-Cacho C., Sebti S.M., Gabrilovich D.I. Regulation of dendritic
cell differentiation and antitumor immune response in cancer by pharmacological selective inhibition of the
Jak2/STAT3 pathway. Cancer Res. 2005, 65:9525-9535
Nefedova Y., Cheng P., Gilkes D., Blaskovich M., Beg A.A., Sebti S.M., Gabrilovich D.I. Activation of dendritic
cells via inhibition of Jak2/STAT3 signaling. J. Immunol. 2005 175: 4338-4346.
Kusmartsev S., Nagaraj S., Gabrilovich D.I. Tumor associated CD8+ T-cell tolerance induced by bone marrow
derived immature myeloid cells. J. Immunol. 2005 175: 4583-4592.
Kusmartsev S., Gabrilovich D.I. Role of immature myeloid cells in mechanisms of immune evasion in cancer.
Cancer Immunol. Immunoth. 2006, 55:237-245
Plescia J., Salz W., Xia1 F., Pennati M., Zaffaroni N., Daidone MG., Meli M., Dohi T., Fortugno P., Nefedova
Y., Gabrilovich DI., Colombo G., Altieri DC. Rational design of shepherdin, a novel anti-cancer agent. Cancer
Cell 2005, 7, 457-468
PHS 398/2590 (Rev. 09/04, Reissued 4/2006)
Page ___ 5____
Maroof A., English N., Bedford P., Gabrilovich D. Knight S. Developing dendritic cells become “lacy” cells,
packed with fat and glycogen. Immunology, 2005 113, 473-485.
Kusmartsev S. and Gabrilovich D.I. STAT1 Signaling Regulates Tumor-Associated Macrophages-mediated Tcell deletion. J. Immunol. 2005, 174, 4880-4891
Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nature
Review Immunol., 2004, 4, 941-952
Wang T., Niu G., Kortylewski, M., Burdelya L., Shain K., Zhang S., Bhattacharya R., Gabrilovich D, Heller R.,
Coppola D., Dalton W., Jove R., Pardoll D., Yu H. Regulation of the innate and adaptive immune responses by
STAT-3 signaling in tumor cells. Nature Med. 2004, 10, 48-54
Nefedova Y., Cheng P., Alsina M., Dalton W.S., Gabrilovich D.I. Notch-1 signaling is involved in bone marrow
stroma mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood 2004,
103, 3503-3510
Kusmartsev S., Nefedova Y., Yoder D., Gabrilovich D.I. Antigen-specific Inhibition of CD8+ T cell Response by
Immature Myeloid Cells in Cancer is Mediated by Reactive Oxygen Species. J. Immunol. 2004, 172: 989-999
Nefedova Y., Huang M., Kusmartsev S., Bhattacharya R., Cheng P., Salup R., Jove R., Gabrilovich D.I.
Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J. Immunol. 2004,
172, 464-474
Cheng P., Nefedova Y., Miele L., Osborne B.A., Gabrilovich D.I. Notch signaling is necessary but not sufficient
for differentiation of dendritic cells. Blood, 2003, 102:3980-3988.
Pisarev V., Yu B., Salup R., Sherman S., Altieri D.C., Gabrilovich D. Full-length dominant negative survivin for
cancer immunotherapy. Clin. Cancer Res. 2003 9(17): 6523-6533
Kusmartsev S. and Gabrilovich D. I. Inhibition of myeloid cell differentiation in cancer: the role of reactive
oxygen species. J. Leuk. Biol. 2003 74: 186-196
Kusmartsev S., Cheng F., Yu B., Nefedova Y., Sotomayor E., Lush R., Gabrilovich D.I. All-trans-retinoic acid
eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer
Res. 2003, 63, 4441-4449.
Ohm J.E., Gabrilovich D.I., Kisseleva E., Carbone D.P. VEGF inhibits T cell development and may contribute
to tumor-induced immuneosuppression". Blood 2003 101: 4878-4886
Yu B., Kusmartsev S., Cheng F., Paolini M., Nefedova Y., Sotomayor E., Gabrilovich DI. Effective combination
of chemotherapy and dendritic cell administration in treatment of advanced stage experimental breast cancer.
Clin. Cancer Res. 2003, 9: 285-294
Gabrilovich D.I., Cheng P., Fan Y., Yu, B., Nikitina E., Sirotkin A., Shurin M., Oyama, T., Adachi Y., Nadaf S.,
Carbone D.P., Skoultchi A.I. H1o histone and differentiation of dendritic cells. A molecular target for tumorderived factors. J. Lekoc. Biol. 2002, 72, 285-296
Nikitina E.Yu, Chada S., Muro-Cacho C., Fang B., Zhang R., Roth J.A., Gabrilovich D.I. An effective
immunization and cancer treatment with activated dendritic cells transduced with full-length wild-type p53.
Gene Therapy 2002, 5, 345-355
Cheng P., Zlobin A., Volgina V., Gottipati S., Osborne B., Miele L., Gabrilovich D.I. Notch-1 regulates NF-kappa
B activity in hematopoietic progenitor cells. J. Immunol. 2001, 167, 4458-4467
Nikitina, E.Yu. and Gabrilovich D.I. Combination of γ-irradiation and dendritic cell administration induces a
potent antitumor response in tumor-bearing mice. An approach to treatment of advanced stage cancer. Intern.
J. Cancer. 2001 94, 825-833
Gabrilovich D.I., Velders MP., Sotomayor E., Kast W.M. Mechanism of immune dysfunction in cancer mediated
by immature Gr-1+ myeloid cells. J. Immunol. 2001, 166, 5398-5406.
Dikov M., Oyama T.,Cheng P., Takahashi T., Takahashi K., Sepetavec T., Edwards B., Adachi Y., Nadaf S.,
Daniel T., Gabrilovich D.I., Carbone D.P. Vascular Endothelial Growth Factor effects on NF-kB activation in
hematopoietic progenitor cells. Cancer Res. 2001, 61, 2015-2021
Nikitina E., Clark J.I., van Beynen J., Chada S., Virmani A.K., Carbone D.P., Gabrilovich D.I. Dendritic Cells
Transduced with Full-Length Wild-Type p53 Generate Antitumor Cytotoxic T lymphocytes from Peripheral
Blood of Cancer Patients. Clin. Cancer Res. 2001, 7, 127-135
Almand B., Clark J.I., Nikitina E., English N.R., Knight S.C., Carbone D.P., Gabrilovich D.I. Increased
production of immature myeloid cells in cancer patients. J. Immunol. 2001, 166, 678-689
Almand, B., Resser, J.R., Lindman, B., Nadaf, S., Clark, J.I., Kwon, E.D., Carbone, D.P., Gabrilovich, D.I.
PHS 398/2590 (Rev. 09/04, Reissued 4/2006)
Page ___ 6____
Clinical significance of defective dendritic cell differentiation in cancer. Clin. Cancer. Res. 2000, 6, 1755-1766
Gabrilovich DI, Ishida T., Nadaf S., Ohm J., Carbone DP. Effects of Anti-VEGF antibody on dendritic cell
function and the efficacy of cancer immunotherapy. Clin.Cancer Res. 1999, 5, 2963-2970.
Ishida, T., Chada, S., Stipanov, M., Nadaf, S, Ciernik, F.I., Gabrilovich, D.I., Carbone, D.P. Dendritic cells
transduced with wild type p53 gene elicit potent antitumor immune responses Clin. Exper. Immunol. 1999;
117, 244-251.
Gabrilovich D.I., Ishida T., Oyama T., Ran S., Kravtsov V., Nadaf S., Carbone D.P. Vascular endothelial
growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple
hematopoietic lineages in vivo. Blood 1998; 92, 4150-4166
Ishida T., Oyama T., Carbone D.P., Gabrilovich D.I. Defective function of Langerhans cells in tumor-bearing
animals is the result of defective maturation from hematopoietic progenitors. J. Immunol. 1998; 161: 4842
Oyama T., Ran S, Ishida T, Nadaf S, Kerr L, Carbone DP, Gabrilovich DI. Vascular endothelial growth factor
affects dendritic cell maturation through the inhibition of NF-kB in hematopoetic progenitor cells J. Immunol.
1998, 160, 1224-1232.
C. Research Support
Ongoing Research Support
Multiple Myeloma Research Foundation, Senior Research Award. Notch signaling as a new molecular target.
(PI-Gabrilovich DI) (11/1/05-10/31/06). Goal is to test in preliminary studies the possibility of using Notch
signaling as a target in treatment of multiple myeloma.
NIH 5RO1 CA 84488 – Correction of dendritic cell defects in cancer (04/99-12/07) (PI- Gabrilovich). Goal is to
investigate the cellular mechanisms of immune suppression in cancer caused by immature myeloid cells and
possible approaches to its correction.
NIH RO1 CA 100062– Mechanism of dendritic cell differentiation in cancer. (07/04-06/09) (PI- Gabrilovich DI).
Goal is to investigate role of Notch and STAT3 signaling in dendritic cell differentiation in cancer.
NIH R21 CA101324 - ATRA effect on myeloid cell differentiation in cancer (07/04-06/2006) (PI-Gabrilovich DI).
Goal is to investigate the effect of ATRA on myeloid cell differentiation in patients with metastatic kidney
cancer.
Cancer Treatment Research Foundation G-04-066 - Combination of external beam radiation with intratumoral
injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients (03/01/0602/28/08) (PI-Gabrilovich D.I.) Goal: To conduct phase I/II clinical trial
NIH/NCI 1R01CA107493 - Overcoming DC defects in cancer patients by VEGF trap (10/1/04-09/30/06) (PIJ. Sosman, Vanderbilt University, Gabrilovich- PI for subcontract). Goal is to evaluate the effect on DC
phenotype and function of new anti-VEGF therapy utilizing VEGF-trap construct (soluble receptor).
Completed Research Support
American Cancer Society RSG–02-154-01-CCE - Immunotherapy with dendritic cells transduced with wild-type
p53 (07/02-06/06) (PI-Gabrilovich DI). Goal was to develop new methods of cancer immunotherapy based on
immunization with p53 transduced DCs.
NIH RO1 CA84270 - Regulation of dendritic cells generation and function by tumor (01/00-01/03) (PI– M.
Shurin, University of Pittsburgh, PI for subcontract – Gabrilovich DI). Goal was to study the role of NF-kB as
possible target for tumor-derived factors during DC differentiation.
Florida ACS 01/01/02-12/31/02 – Survivin in immunotherapy of cancer (PI-Gabrilovich). The goal was to
investigate a possibility of using survivin as new tumor associated antigen
NIH 5RO1 CA84106 – 08/01/02 – 07/31/04 Enhancement of T cell responses against survivin. (PI - S.
Sherman, University of Nebraska, Co-PI and PI for subcontract-Gabrilovich DI). Goal of this project is to
PHS 398/2590 (Rev. 09/04, Reissued 4/2006)
Page ___ 7____
develop new liposomal formulations to enhance T cells response in mice to tumor antigens
PHS 398/2590 (Rev. 09/04, Reissued 4/2006)
Page ___ 8____